---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-036886"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:18:36.863951+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M

## Summary
- Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
- Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.
- Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.
- Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.
- Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth.

## SEC filing metadata
- accession: 0001213900-26-036886
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/0001213900-26-036886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/ea0283899-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-036886
- JSON: https://secwatch.observer/filing/0001213900-26-036886.json
- Plain text: https://secwatch.observer/filing/0001213900-26-036886.txt

## Key facts
- Earnings Releases
  Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.
  - Period: the year ended December 31, 2025
  - Revenue: $12.5 million
  - Net income: net loss of $7.2 million, or $0.11 per share
  - EPS: $0.11 per share
  - Result: reported results
  source text: Net revenues for the year ended December 31, 2025 were $12.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/0001213900-26-036886-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.